07:14 AM EDT, 06/10/2024 (MT Newswires) -- Moderna ( MRNA ) said Monday a phase 3 trial of its investigational combination vaccine mRNA-1083, targeting influenza and Covid-19, met its primary endpoints, with the vaccine demonstrating a "higher immune response" compared to licensed comparator vaccines in adults 50 years and older.

The combination vaccine contains components of Moderna's ( MRNA ) seasonal influenza vaccine candidate and next-generation Covid-19 vaccine candidate, according to Moderna ( MRNA ).

The mRNA-1083 investigational vaccine also demonstrated an "acceptable tolerability and safety profile," with most adverse reactions considered grade 1 or 2 in severity and consistent with those from the licensed vaccines, the company said.

Moderna ( MRNA ) said it will engage with regulators on next steps.

Price: 153.39, Change: +2.38, Percent Change: +1.58